Globus Medical (GMED) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Leerink Partners Raises Price Target on Globus Medical (GMED) Following 2Q Results
July 31, 2015 9:46 AM EDTLeerink Partners reiterated an Outperform rating on Globus Medical (NYSE: GMED), and raised the price target to $32.00 (from $30.00), following 2Q results. 2Q sales of $134MM beat consensus by $7M. EPS was reported in line with consensus estimates of $0.25. GMED raised 2015 revenue... More
